CN1291756C - 通过活化血红蛋白清除剂受体生产血细胞 - Google Patents
通过活化血红蛋白清除剂受体生产血细胞 Download PDFInfo
- Publication number
- CN1291756C CN1291756C CNB028014294A CN02801429A CN1291756C CN 1291756 C CN1291756 C CN 1291756C CN B028014294 A CNB028014294 A CN B028014294A CN 02801429 A CN02801429 A CN 02801429A CN 1291756 C CN1291756 C CN 1291756C
- Authority
- CN
- China
- Prior art keywords
- cell
- antibody
- purposes
- cfu
- colony
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
Description
%CD45+/CD34+ | %IgG1同型对照 | %CD163+ | |
ABM CD34+细胞 | 95 | 1.9 | 75.1 |
制剂 | %CD163+ | %CD34+ | %CD34+/CD163+ |
从ABM富集的CD34+细胞(n=4) | 1.6 | 87.9 | 1.7 |
从UCB富集的CD34+细胞(n=2) | 2.8 | 25.5 | 3.8 |
No.of BFU-E/1×103细胞 | |||
细胞来源 | -Anti-CD163 Ab | +Anti-CD163 Ab | RFI |
UCB CD34+ | 28 | 42 | 1.5x |
ABM CD34+ | 22 | 29 | 1.3x |
BFU-E集落数/平板 | ||||
抗体 | [Epo],U/mL | -抗CD163 Ab | +抗CD163 Ab | RFI* |
EDHu-1 | 0.2 | 29 | 38 | 1.3 |
2.0 | 48 | 72 | 1.5 | |
Mac158 | 0.2 | 33 | 41 | 1.3 |
2.0 | 48 | 74 | 1.5 |
CD163+细胞 | CD14+细胞 | CD163+/CD14+ | |
CFU-GM来源细胞 | 10.6% | 42.0% | 1.4 |
Claims (20)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27845301P | 2001-03-26 | 2001-03-26 | |
US60/278,453 | 2001-03-26 | ||
US34179301P | 2001-12-21 | 2001-12-21 | |
US60/341,793 | 2001-12-21 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2006101439647A Division CN1952119A (zh) | 2001-03-26 | 2002-03-26 | 通过活化血红蛋白清除剂受体生产血细胞 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1462192A CN1462192A (zh) | 2003-12-17 |
CN1291756C true CN1291756C (zh) | 2006-12-27 |
Family
ID=26959110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB028014294A Expired - Fee Related CN1291756C (zh) | 2001-03-26 | 2002-03-26 | 通过活化血红蛋白清除剂受体生产血细胞 |
Country Status (12)
Country | Link |
---|---|
US (1) | US7524500B2 (zh) |
EP (1) | EP1372716B1 (zh) |
JP (1) | JP4326803B2 (zh) |
KR (1) | KR100938625B1 (zh) |
CN (1) | CN1291756C (zh) |
AT (1) | ATE421886T1 (zh) |
AU (1) | AU2002247577B2 (zh) |
CA (1) | CA2441566C (zh) |
DE (1) | DE60231031D1 (zh) |
ES (1) | ES2320860T3 (zh) |
NZ (1) | NZ528832A (zh) |
WO (1) | WO2002076501A2 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5047803B2 (ja) * | 2004-11-19 | 2012-10-10 | トリリウム ダイアグノスティクス,エルエルシー | 白血球FcγRI受容体(CD64)の定量化のための、ソフトウェアを統合したフローサイトメトリーアッセイ |
WO2006094402A1 (en) * | 2005-03-10 | 2006-09-14 | Hemosol Lp | Novel hemoglobin scavenger receptor, cd163, and method of increasing cd163 expression on human stem cells and stimulation of erythroid progenitors |
US9388382B2 (en) | 2005-10-05 | 2016-07-12 | The Board Of Trustees Of The University Of Illinois | Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells |
US8835163B2 (en) | 2006-10-18 | 2014-09-16 | The Board Of Trustees Of The University Of Illinois | Embryonic-like stem cells derived from adult human peripheral blood and methods of use |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1328297E (pt) * | 2000-10-16 | 2010-01-04 | Cytoguide Aps | Função de um receptor de haptoglobina-hemoglobina e suas utilizações |
-
2002
- 2002-03-26 WO PCT/CA2002/000411 patent/WO2002076501A2/en active IP Right Grant
- 2002-03-26 EP EP02716567A patent/EP1372716B1/en not_active Expired - Lifetime
- 2002-03-26 AT AT02716567T patent/ATE421886T1/de not_active IP Right Cessation
- 2002-03-26 DE DE60231031T patent/DE60231031D1/de not_active Expired - Lifetime
- 2002-03-26 KR KR1020027016020A patent/KR100938625B1/ko not_active IP Right Cessation
- 2002-03-26 JP JP2002575014A patent/JP4326803B2/ja not_active Expired - Fee Related
- 2002-03-26 CA CA2441566A patent/CA2441566C/en not_active Expired - Fee Related
- 2002-03-26 ES ES02716567T patent/ES2320860T3/es not_active Expired - Lifetime
- 2002-03-26 CN CNB028014294A patent/CN1291756C/zh not_active Expired - Fee Related
- 2002-03-26 US US10/471,604 patent/US7524500B2/en not_active Expired - Fee Related
- 2002-03-26 AU AU2002247577A patent/AU2002247577B2/en not_active Ceased
- 2002-03-26 NZ NZ528832A patent/NZ528832A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20030036196A (ko) | 2003-05-09 |
EP1372716B1 (en) | 2009-01-28 |
KR100938625B1 (ko) | 2010-01-22 |
JP4326803B2 (ja) | 2009-09-09 |
US7524500B2 (en) | 2009-04-28 |
EP1372716A2 (en) | 2004-01-02 |
US20040151692A1 (en) | 2004-08-05 |
JP2004525932A (ja) | 2004-08-26 |
CA2441566C (en) | 2011-02-22 |
ATE421886T1 (de) | 2009-02-15 |
WO2002076501A3 (en) | 2003-05-30 |
AU2002247577B2 (en) | 2007-04-26 |
NZ528832A (en) | 2008-08-29 |
CA2441566A1 (en) | 2002-10-03 |
DE60231031D1 (de) | 2009-03-19 |
WO2002076501A2 (en) | 2002-10-03 |
CN1462192A (zh) | 2003-12-17 |
ES2320860T3 (es) | 2009-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1272136A (zh) | 体外造血细胞的刺激 | |
CN1564864A (zh) | 造血干细胞的制备方法 | |
CN1379815A (zh) | Baff受体(bcma),一种免疫调节剂 | |
CN109593711A (zh) | 扩增自然杀手细胞部份的扩增方法及用途 | |
WO2016184427A1 (zh) | 低氧处理的间充质干细胞及其应用 | |
CN1190348A (zh) | 用于增加造血细胞的方法 | |
CN102643784A (zh) | 一种造血干/祖细胞的体外扩增体系 | |
CN1291756C (zh) | 通过活化血红蛋白清除剂受体生产血细胞 | |
CN1311071C (zh) | 一种治疗自身免疫病的方法 | |
CN1835679A (zh) | 人源免疫活性细胞的制备方法 | |
CN100346823C (zh) | 用于调节免疫反应的釉质基质蛋白组合物 | |
CN106659560B (zh) | 生殖腺来源的侧群干细胞 | |
CN105861434A (zh) | 自体nk细胞及其培养方法和应用 | |
CN1844149A (zh) | 抗人4-1bbl单克隆抗体制备及其应用 | |
CN115287266A (zh) | 一种靶向于猪RORγt的单克隆抗体及其杂交瘤细胞株和应用 | |
CN1952119A (zh) | 通过活化血红蛋白清除剂受体生产血细胞 | |
KR102032384B1 (ko) | 제대혈 단핵세포에서의 자연살해세포의 제조 방법 | |
CN113416701B (zh) | 一种nk细胞培养基及培养方法 | |
AU2002247577A1 (en) | Blood cell production via activation of the hemoglobin scavenger receptor | |
US20230355675A1 (en) | Compositions and methods for producing and using ilcs to treat health conditions | |
CN1798834A (zh) | 使造血干细胞移植后附着生长稳定的组合物、用于获取该组合物的试剂盒、使造血干细胞移植后附着生长稳定的方法、人单克隆抗体和多克隆抗体及其制备方法、编码人单克隆抗体的基因以及导入了该基因的重组细胞 | |
CN1844145A (zh) | 抗人ox40l单克隆抗体的制备及其应用 | |
JPH07508640A (ja) | 幹細胞増殖因子 | |
CN1754574A (zh) | 使用免疫细胞治疗血液缺损症和骨髓抑制 | |
Manlove | Anti-leukemia immunity is enabled by unmasking cross-reactive antigens with vaccination and checkpoint blockade |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HOMUSOER LIMITED PARTNERSHIP CO.,LTD. Free format text: FORMER OWNER: HEMOSOL INC. Effective date: 20070112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20070112 Address after: Ontario Patentee after: Hemosol LP Address before: Ontario Patentee before: Hemosol Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: SERAPLY BIOLOGY PHARMACY CO.,LTD. Free format text: FORMER OWNER: HEMSOUR LIMITED PARTNERSHIP LIMITED PARTNERSHIP COMPANY Effective date: 20091120 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091120 Address after: Ontario Patentee after: Serra Pury biopharmaceutical Address before: Ontario Patentee before: Hemosol LP |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061227 Termination date: 20180326 |
|
CF01 | Termination of patent right due to non-payment of annual fee |